Stock 301201 CHENGDA PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ChengDa Pharmaceuticals Co., Ltd.

Equities

301201

CNE100005766

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
19.98 CNY +1.78% Intraday chart for ChengDa Pharmaceuticals Co., Ltd. -0.65% -21.43%
May. 14 ChengDa Pharmaceuticals Co., Ltd. Approves Cash Dividend for 2023 CI
Apr. 21 ChengDa Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 4,912 3,934
Enterprise Value (EV) 1 3,531 2,570
P/E ratio 45.2 x 43.2 x
Yield 0.59% 0.79%
Capitalization / Revenue 11.9 x 9.5 x
EV / Revenue 8.58 x 6.2 x
EV / EBITDA 33.5 x 26.2 x
EV / FCF -18.4 x -55 x
FCF Yield -5.43% -1.82%
Price to Book 2.22 x 1.73 x
Nbr of stocks (in thousands) 154,714 154,714
Reference price 2 31.75 25.43
Announcement Date 4/23/23 4/21/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 373 415.7 411.5 414.3
EBITDA 1 128.3 142.6 105.5 97.99
EBIT 1 101.9 112.1 70.27 57.68
Operating Margin 27.32% 26.96% 17.08% 13.92%
Earnings before Tax (EBT) 1 139.5 115.3 120.1 104.2
Net income 1 121.2 100.4 106.5 90.98
Net margin 32.48% 24.16% 25.88% 21.96%
EPS 2 1.044 0.8656 0.7029 0.5881
Free Cash Flow 1 57.1 -98.29 -191.8 -46.73
FCF margin 15.31% -23.64% -46.61% -11.28%
FCF Conversion (EBITDA) 44.52% - - -
FCF Conversion (Net income) 47.12% - - -
Dividend per Share - 0.4500 0.1875 0.2000
Announcement Date 4/18/22 4/18/22 4/23/23 4/21/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - 50.6 - -
Net Cash position 1 37 - 1,381 1,364
Leverage (Debt/EBITDA) - 0.3547 x - -
Free Cash Flow 1 57.1 -98.3 -192 -46.7
ROE (net income / shareholders' equity) 29.3% 20.3% 7.76% 4.05%
ROA (Net income/ Total Assets) 11.8% 11.5% 2.92% 1.51%
Assets 1 1,028 872.8 3,643 6,028
Book Value Per Share 2 3.950 4.560 14.30 14.70
Cash Flow per Share 2 0.4100 0.1600 3.910 8.820
Capex 1 63.8 139 206 225
Capex / Sales 17.11% 33.36% 49.99% 54.23%
Announcement Date 4/18/22 4/18/22 4/23/23 4/21/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CHENGDA PHARMACEUTICALS CO., LTD. Stock ChengDa Pharmaceuticals Co., Ltd.
-21.43% 419M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 301201 Stock
  4. Financials ChengDa Pharmaceuticals Co., Ltd.